Literature DB >> 7136627

Incidence and survival curves of cystic fibrosis in Sweden.

H Kollberg.   

Abstract

A registry of all patients with cystic fibrosis (CF) in Sweden has been kept since 1968. During the 10-year period 1968-1977 the number of CF patients in Sweden increased by about 8-9 per year, i.e. from 116 to 200, the median age of patients increased from 5 to 11 years, the percentage of patients above 18 years of age increased from 3 to 9 of the total CF population, and the median survival age increased from 7.5 to 16 years. For CF patients born without meconium ileus the median survival age in 1973-1977 was 17.8 years. From these figures the incidence of CF in Sweden is estimated to be 1 : 2200 to 1 : 4500. Several factors may have contributed to the improved outcome for CF patients, such as better medical treatment with more intensive physical therapy, the use of inhalation therapy and new antibiotics, improved social care and intensified information.

Entities:  

Mesh:

Year:  1982        PMID: 7136627     DOI: 10.1111/j.1651-2227.1982.tb09399.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  4 in total

1.  Cystic fibrosis: current survival and population estimates to the year 2000.

Authors:  J S Elborn; D J Shale; J R Britton
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

2.  394delTT: a Nordic cystic fibrosis mutation.

Authors:  M Schwartz; M Anvret; M Claustres; H G Eiken; K Eiklid; C Schaedel; L Stolpe; L Tranebjaerg
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

3.  High incidence of cystic fibrosis on the Faroe Islands: a molecular and genealogical study.

Authors:  M Schwartz; N Sørensen; N J Brandt; E Høgdall; T Holm
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

4.  Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study.

Authors:  Anne L Stephenson; Jenna Sykes; Sanja Stanojevic; Bradley S Quon; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza K Fink; Alexander Elbert; Christopher H Goss
Journal:  Ann Intern Med       Date:  2017-03-14       Impact factor: 25.391

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.